In the United States, a retrospective study was done among 1026 ischemic stroke patients in which 513 were treated with tPA and 513 were not; It concluded that those treated with intravenous tPA experienced long-term clinical advantages in survival and functional status.23 Another cohort study with five years follow-up (1317 patients treated with intravenous thrombolysis and 1317 patients not treated with intravenous thrombolysis) concluded in 2021 that thrombolysis in acute ischemic stroke reduced short-term mortality by 47% and did not significantly reduce long-term mortality.24 The gene discussed is PLAT; the disease is ischemic stroke.